Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn, C., Snee, M., Ashcroft, L. et al. (17 more authors) (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Faivre-Finn, C.
  • Snee, M.
  • Ashcroft, L.
  • Appel, W.
  • Barlesi, F.
  • Bhatnagar, A.
  • Bezjak, A.
  • Cardenal, F.
  • Fournel, P.
  • Harden, S.
  • Le Pechoux, C.
  • McMenemin, R.
  • Mohammed, N.
  • O'Brien, M.
  • Pantarotto, J.
  • Surmont, V.
  • Van Meerbeeck, J.P.
  • Woll, P.J. https://orcid.org/0000-0002-1118-0831
  • Lorigan, P.
  • Blackhall, F.
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/)
Dates:
  • Published: 19 June 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 19 Jul 2017 11:27
Last Modified: 19 Jul 2017 11:27
Published Version: https://doi.org/10.1016/S1470-2045(17)30318-2
Status: Published online
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S1470-2045(17)30318-2
Related URLs:

Share / Export

Statistics